Synapse Open Synapse
Patents & IP

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

IP Kat · · 9 min read

Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure.

Latest from IP Kat